Considering that HOXB5 was increased in CRPC and NEPC and was involved in cell growth, invasion, and resistance to enzalutamide and apalutamide in PCa, HOXB5 may be a promising therapeutic target. Here, HOXB5 is linked to posterior cortical atrophy.